Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCALET: Cabozantinib and Lanreotide for Advanced GEP-NET
NCT05048901Phase 2Recruiting
- Sponsor
- National Health Research Institutes
- Start
- Sep 2021
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by National Health Research Institutes. Primary endpoints: Maximal Tolerated Dose at 28 days and Progression-Free Survival up to 72 months. Started Sep 2021; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT05048901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048901.